FOLFOX plus ziv‐aflibercept or placebo in first‐line metastatic esophagogastric adenocarcinoma: A double‐blind, randomized, multicenter phase 2 trial
James M. Cleary(Brigham and Women's Hospital), Peter C. Enzinger(Dana-Farber Cancer Institute), Jeffrey A. Meyerhardt(CancerCare), Yves Boucher(Harvard University), Douglas A. Rubinson(Harvard University), Thomas A. Abrams(Dana-Farber Cancer Institute), Charles S. Fuchs(University of Southern California), Christopher G. Azzoli(Massachusetts General Hospital), Nadine J. McCleary(Harvard University), Lipika Goyal(Stanford Medicine), Jennifer A. Chan(University of Calgary), Nora Horick(Massachusetts General Hospital), Gabriel A. Brooks(Dartmouth Institute for Health Policy and Clinical Practice), Kimmie Ng(Dana-Farber Cancer Institute), Kathryn Gibb(California Department of Public Health), Lawrence S. Blaszkowsky(Brigham and Women's Hospital), Jeffrey W. Clark(Massachusetts General Hospital), Deborah Schrag(Dana-Farber Brigham Cancer Center), Christopher Graham(Harvard University), Bridget Fitzpatrick(Dana-Farber Cancer Institute), Matthew B. Yurgelun(Dana-Farber Cancer Institute), Diane Savarese(University of Massachusetts Chan Medical School), Dan G. Duda(Harvard University)
Cited by 24
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
How To Build and Interpret a Nomogram for Cancer Prognosis
|Journal of Clinical Oncology|2008|3.4k
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k
Diagnosis and Treatment of Metastatic Colorectal Cancer
|JAMA|2021|2.6k